Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons
- PMID: 23072344
- PMCID: PMC3581041
- DOI: 10.1089/aid.2012.0234
Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons
Abstract
Data on weight gain and the progression to overweight/obesity in HIV-infected persons during initial combination antiretroviral therapy (cART) are limited, and comparisons to the general population are inconclusive. Weight and body mass index (BMI) changes were studied in HIV-infected adults who remained on initial cART for 12 consecutive months and in an HIV-uninfected cohort receiving care at Duke University Medical Center between 1998 and 2008. Overweight/obesity was defined as BMI ≥25 kg/m(2). Variables were analyzed by Chi-square and Student's t-tests. Ninety-two HIV-infected persons (median age 38.2 years) met inclusion criteria. Weight and BMI increased during 12 months of cART (80.0 to 84.4 kg, p<0.0001; 26.4 to 27.9 kg/m(2), p<0.0001; respectively). Weight gain was greater in HIV-infected females compared to males (8.6 vs. 3.6 kg, p=0.04), in persons treated with protease inhibitor (PI)-based cART compared to non-PI-based cART (9.0 vs. 2.7 kg, p=0.001), and in persons with a pretreatment CD4 count <200 cells/mm(3) compared to ≥200 cells/mm(3) (8.9 vs. 0.3 kg, p<0.0001). Overweight/obesity prevalence increased from 52% to 66% during 12 months of initial cART, a 27% relative increase (p=0.002). HIV-infected persons had a lower prevalence of pretreatment overweight/obesity compared to 94 age-matched control subjects (52% vs. 91%, p<0.001); however, there was no change in weight (92.7 vs. 93.0 kg, p=0.5) or overweight/obesity prevalence (91% to 92%, p>0.9) during 12 months in the control cohort. Management should anticipate excess weight gain during the first year of cART in persons who are female, have a pretreatment CD4 <200 cells/mm(3), or will initiate PI-based cART.
Figures

Similar articles
-
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada.AIDS Res Hum Retroviruses. 2016 Jan;32(1):50-8. doi: 10.1089/aid.2015.0147. Epub 2015 Sep 9. AIDS Res Hum Retroviruses. 2016. PMID: 26352511 Free PMC article.
-
HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy.J Womens Health (Larchmt). 2018 Sep;27(9):1162-1169. doi: 10.1089/jwh.2017.6717. Epub 2018 Apr 2. J Womens Health (Larchmt). 2018. PMID: 29608129 Free PMC article.
-
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.Clin Infect Dis. 2011 Nov;53(9):952-60. doi: 10.1093/cid/cir606. Epub 2011 Sep 26. Clin Infect Dis. 2011. PMID: 21946189 Free PMC article.
-
[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Enferm Infecc Microbiol Clin. 2011. PMID: 21388714 Spanish.
-
[GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].Enferm Infecc Microbiol Clin. 2015 Oct;33(8):543.e1-43. doi: 10.1016/j.eimc.2015.03.016. Epub 2015 May 7. Enferm Infecc Microbiol Clin. 2015. PMID: 25959461 Spanish.
Cited by
-
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV.HIV Med. 2022 Mar;23(3):274-286. doi: 10.1111/hiv.13211. Epub 2021 Nov 23. HIV Med. 2022. PMID: 34816562 Free PMC article.
-
High risk of obesity and weight gain for HIV-infected uninsured minorities.J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e33-40. doi: 10.1097/QAI.0000000000000010. J Acquir Immune Defic Syndr. 2014. PMID: 24121754 Free PMC article.
-
The ongoing need for good physiological investigation: obstructive sleep apnea in HIV patients as a paradigm.J Appl Physiol (1985). 2015 Jan 15;118(2):244-6. doi: 10.1152/japplphysiol.00656.2014. Epub 2014 Aug 21. J Appl Physiol (1985). 2015. PMID: 25150224 Free PMC article. No abstract available.
-
Prevalence of Frailty Phenotypes in Older People Living with HIV: A Cross-Sectional Study from Brazil.J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241241169. doi: 10.1177/23259582241241169. J Int Assoc Provid AIDS Care. 2024. PMID: 38715366 Free PMC article.
-
Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy.AIDS Res Hum Retroviruses. 2013 Jul;29(7):1019-25. doi: 10.1089/aid.2013.0016. Epub 2013 Apr 11. AIDS Res Hum Retroviruses. 2013. PMID: 23469772 Free PMC article.
References
-
- Amorosa V. Synnestvedt M. Gross R. Freidman H. MacGregor RR. Gudonis D. Frank I. Tebas P. A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–561. - PubMed
-
- NIH publication no. 98-4083. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; Bethesda, MD: 1998. NHLBI Obesity Education Initiative: Clinical guidelines on the identification, evaluation, treatment of overweight, obesity in adults: The evidence report.
-
- Klein D. Hurley LB. Quesenberry CP. Sidney S. Do protease inhibitors increase the risk of coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471–477. - PubMed
-
- Currier JS. Taylor A. Boyd F. Dezil CM. Kawabata H. Burtcel B. Maa JF. Hodder S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous